Altamira Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference September 9-11
Altamira Therapeutics (Nasdaq: CYTO), a company focused on RNA delivery technology for targets beyond the liver, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event will take place both virtually and in person from September 9-11, 2024, at the Lotte New York Palace Hotel in New York City.
Thomas Meyer, the founder, Chairman, and CEO of Altamira, will deliver an on-demand presentation starting at 7:00am ET on September 09, 2024. Registered attendees will have the opportunity to submit questions for the company after the presentation becomes available. Investors interested in scheduling a one-on-one meeting with Mr. Meyer are encouraged to email meetings@hcwco.com.
Altamira Therapeutics (Nasdaq: CYTO), un'azienda focalizzata sulla tecnologia di somministrazione dell'RNA per obiettivi oltre il fegato, ha annunciato la sua partecipazione alla 26ª Conferenza Globale Annuale sugli Investimenti H.C. Wainwright. L'evento si svolgerà sia virtualmente che di persona dal 9 all'11 settembre 2024, presso il Lotte New York Palace Hotel a New York City.
Thomas Meyer, fondatore, Presidente e CEO di Altamira, presenterà una conferenza on-demand a partire dalle 7:00 ET del 9 settembre 2024. I partecipanti registrati avranno l'opportunità di inviare domande all'azienda dopo che la presentazione sarà disponibile. Gli investitori interessati a pianificare un incontro individuale con il signor Meyer sono invitati a inviare un'email a meetings@hcwco.com.
Altamira Therapeutics (Nasdaq: CYTO), una empresa centrada en la tecnología de entrega de ARN para objetivos más allá del hígado, ha anunciado su participación en la 26ª Conferencia Global Anual de Inversión H.C. Wainwright. El evento se llevará a cabo tanto de manera virtual como presencial del 9 al 11 de septiembre de 2024, en el Lotte New York Palace Hotel en la ciudad de Nueva York.
Thomas Meyer, fundador, Presidente y CEO de Altamira, ofrecerá una presentación a demanda comenzando a las 7:00 am ET del 9 de septiembre de 2024. Los asistentes registrados tendrán la oportunidad de enviar preguntas a la empresa después de que la presentación esté disponible. Los inversores interesados en programar una reunión uno a uno con el Sr. Meyer están invitados a enviar un correo electrónico a meetings@hcwco.com.
Altamira Therapeutics (Nasdaq: CYTO), 간 이외의 목표를 위한 RNA 전달 기술에 중점을 둔 회사가 H.C. Wainwright 제26회 연례 글로벌 투자 컨퍼런스에 참여한다고 발표했습니다. 이 행사는 2024년 9월 9일부터 11일까지 뉴욕시의 Lotte New York Palace Hotel에서 온라인과 오프라인으로 진행됩니다.
Altamira의 창립자이자 회장 및 CEO인 Thomas Meyer가 2024년 9월 9일 오전 7:00 ET에 온디맨드 프레젠테이션을 진행합니다. 등록된 참석자들은 프레젠테이션이 제공된 후 회사에 질문을 제출할 수 있는 기회를 가집니다. Meyer 씨와 개별 회의를 예약하고자 하는 투자자는 meetings@hcwco.com으로 이메일을 보내주시기 바랍니다.
Altamira Therapeutics (Nasdaq: CYTO), une entreprise axée sur la technologie d'administration d'ARN pour des cibles au-delà du foie, a annoncé sa participation à la 26e Conférence mondiale annuelle sur les investissements H.C. Wainwright. L'événement se déroulera tant en virtuel qu'en personne du 9 au 11 septembre 2024, à l'Hôtel Lotte New York Palace à New York.
Thomas Meyer, le fondateur, président et PDG d'Altamira, fera une présentation à la demande à partir de 7h00 ET le 9 septembre 2024. Les participants inscrits auront la possibilité de soumettre des questions à l'entreprise après que la présentation soit disponible. Les investisseurs intéressés par la planification d'une réunion en tête-à-tête avec M. Meyer sont encouragés à envoyer un e-mail à meetings@hcwco.com.
Altamira Therapeutics (Nasdaq: CYTO), ein Unternehmen, das sich auf RNA-Delivery-Technologie für Ziele außerhalb der Leber konzentriert, hat seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright bekannt gegeben. Die Veranstaltung findet sowohl virtuell als auch persönlich vom 9. bis 11. September 2024 im Lotte New York Palace Hotel in New York City statt.
Thomas Meyer, der Gründer, Vorsitzende und CEO von Altamira, wird eine On-Demand-Präsentation ab 7:00 Uhr ET am 9. September 2024 halten. Registrierte Teilnehmer haben die Möglichkeit, Fragen an das Unternehmen zu stellen, sobald die Präsentation verfügbar ist. Investoren, die ein persönliches Treffen mit Herrn Meyer vereinbaren möchten, werden gebeten, eine E-Mail an meetings@hcwco.com zu senden.
- None.
- None.
Hamilton, Bermuda, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced that its founder, Chairman, and CEO Thomas Meyer will be presenting at the H.C. Wainwright 26th Annual Global Investment Conference, being held virtually and in person on September 9-11, 2024, at Lotte New York Palace Hotel in New York City.
Event: H.C. Wainwright Presentation On-Demand
Date: September 09, 2024
Time: 7:00am ET
Webcast: Link
Registration: Link
Please note that Company presentation date and time are subject to change. Attendees may refer to the program agenda for more information. Once the presentation becomes available on-demand, registered attendees can submit their Q&As for the Company. To schedule a 1x1 investor meeting with Mr. Thomas Meyer, please send an email to meetings@hcwco.com.
About Altamira Therapeutics
Altamira Therapeutics (Nasdaq: CYTO) is developing and supplying peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues (OligoPhore™ / SemaPhore™ platforms). The Company currently has two flagship siRNA programs using its proprietary delivery technology: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis, both in preclinical development beyond in vivo proof of concept. The versatile delivery platform is also suited for mRNA and other RNA modalities and made available to pharma or biotech companies through out-licensing. In addition, Altamira holds a
FAQ
When is Altamira Therapeutics (CYTO) presenting at the H.C. Wainwright Global Investment Conference?
Where is the H.C. Wainwright Global Investment Conference taking place in 2024?
How can investors schedule a meeting with Altamira Therapeutics (CYTO) at the conference?
What is the main focus of Altamira Therapeutics (CYTO)?
